GW406381

Phase 3Small molecule

GSK

GW406381 is one of 65 small molecule programs targeting Peripheral Nerve Injury. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral Nerve InjuryActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

OsteoarthritisActive, not recruiting

Peripheral Nerve InjuryPhase 1

Active, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

OsteoarthritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Rituxan

Roche

Preclinical

61 2

GW406381

GSK

Phase 3

1 3

Arcoxia

Novartis

Preclinical

4 4

Ilaris

Novartis

Preclinical

3 5

Celexa

AbbVie

Preclinical

1 6

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 7

Cataflam

Rituxan

7 9

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 10

Cimzia

UCB

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis1 trial

COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis

Completed· GSK logo

GSK·Phase 3·NCT00113308·2,208 enrolled

Moderate Hepatic Impairment1 trial

A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment

Completed· GSK logo

GSK·Phase 1·NCT00373243·24 enrolled

Tooth Extraction1 trial

Dental Pain (Following Third Molar Tooth Extraction) Study

Completed· GSK logo

GSK·Phase 3·NCT00114049·300 enrolled

Osteoarthritis1 trial

Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee

Completed· GSK logo

GSK·Phase 3·NCT00120900·1,340 enrolled

Peripheral Nerve Injury1 trial

GW406381 In Patients With Peripheral Nerve Injury

Completed· GSK logo

GSK·Phase 1·NCT00279032·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for GW406381. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GW406381 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GW406381. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

GW406381

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Moderate Hepatic Impairment1 trial

Tooth Extraction1 trial

Osteoarthritis1 trial

Peripheral Nerve Injury1 trial

References

Drug Info

Quick Facts

Related News